Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AutoCyte arranges finance for PREP customers:

This article was originally published in Clinica

Executive Summary

AutoCyte has secured an agreement with Norwest Financial Leasing, part of the Wells Fargo group, to provide financing for laboratories that wish to acquire the company's PREP automated Pap smear preparation system. Under the deal, customers will be able to avoid capital outlay either by leasing the equipment and purchasing test kits, or by paying a higher per-test price that includes a charge for the equipment. Customers may also purchase the equipment outright. AutoCyte recently received FDA approval for the PREP system after a number of setbacks (See Clinica No 864, p 16), and is currently seeking approval for its SCREEN system, which automates the screening of slides prepared with the PREP system. Last month, AutoCyte and fellow Pap smear company NeoPath agreed a $100 million merger (see Clinica No 862, p 11).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT078840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel